Last updated on November 2019

A Phase 3, Randomized , Double Blind, Placebo controlled Study. Investigating the Efficacy and Safety of CVT-301 (Levodopa inhalation Powder) in Parkinson's Disease With Motor Response Fluctuations (Off Phenomena)


Brief description of study

A Phase 3, Randomized , Double Blind, Placebo controlled Study. Investigating the Efficacy and Safety of CVT-301 (Levodopa inhalation Powder) in Parkinson's Disease With Motor Response Fluctuations (Off Phenomena)

Detailed Study Description

For most people with Parkinson's doctors use levodopa to manage symptoms. But, with long term treatment, the effectiveness of the levodopa pills often lessens and lead to off episodes, which include slowness, stiffness and tremors. There are few treatment options to manage these off episodes. A treatment approach that permits levodopa to be more rapidly and predictably absorbed by the body is needed. CVT-301, the investigational medication under evaluation is a dry powder form of levodopa. it is inhaled using an inhaler, potentially allowing the body to absorb the levodopa faster than the traditional pill form.

Before you begin, you will be examined to determine if you are eligible to participate. If eligible, you will be randomly assigned to one of three treatment groups.

You will also be asked to fill in a diary with information about your on and off episodes and timing of medication at home.

Clinical Study Identifier: TX143025

Find a site near you

Start Over

Palm Beach Neurological Center

3365 Burns Rd. Suite 203 Palm Beach Gardens, FL USA
  Connect »